Major 2026 Medicare and FDA Regulatory Changes Impacting Healthcare

The Centers for Medicare & Medicaid Services (CMS) and the US Food and Drug Administration (FDA) have implemented a series of impactful decisions slated for 2026. These regulatory changes are predicted to affect reimbursement, prescribing practices, patient access, and clinical operations across various healthcare specialties.

One significant update is the 2026 Medicare Physician Fee Schedule, effective January 1, 2026. CMS has finalized payment policies, establishing distinct conversion factors for qualifying alternative payment model (APM) participants and non-qualifying participants. This includes a 0.75% statutory update for qualifying APM participants and a 0.25% update for others, integrating a statutory 2.50% increase along with a 0.49% adjustment for work relative value units.

Additionally, the Contract Year 2026 Medicare Advantage and Part D final rule introduces several prescription drug coverage changes. Notably, it eliminates deductible and cost-sharing requirements for certain adult vaccines and limits cost-sharing for covered insulin products, thereby optimizing patient cost-efficiency.

CMS has also revised payment policies for hospital outpatient and ambulatory surgical center services in 2026. There will be a 2.6% rate increase for facilities meeting quality reporting requirements, detailed by a 3.3% market-basket increase offset by a 0.7% productivity adjustment.

The agency emphasizes streamlining healthcare operations with enhanced electronic prior authorization capabilities outlined in the FY 2026 IPPS/LTCH PPS final rule. This initiative is set to boost care delivery efficiency through improved electronic prescribing and benefits verification, complemented by a proposed rule for electronic prior authorization of drugs.

On the FDA front, notable advancements include the approval of Foundayo, an oral GLP-1 therapy, under a rapid pilot program for weight management. The FDA also approved Tzield (teplizumab) for delaying insulin reduction in young Type 1 diabetes patients and cleared Dexcom’s Stelo Glucose Biosensor System for pediatric use, broadening access to continuous glucose monitoring.

Furthermore, the FDA has approved over-the-counter naloxone nasal spray, Rextovy, increasing availability for opioid overdose treatments. Updates to orlistat product labeling now include warnings on the risk of acute kidney injury, underscoring the necessity for healthcare providers to adapt to regulatory compliance requirements and leverage technological advancements for enhanced patient care.